{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:02:38Z","timestamp":1768546958759,"version":"3.49.0"},"reference-count":26,"publisher":"BMJ","issue":"2","funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,7,17]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate associations between baseline presence of erosions and\/or anti-citrullinated protein antibodies (ACPA) on functional ability, disease activity and treatment survival over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Real life data from newly diagnosed rheumatoid arthritis patients were identified in the international METEOR registry. Patients were grouped according to presence\/absence of ACPA and\/or erosions at baseline. Associations between the presence of ACPA and\/or erosions (four groups) with the change of Disease Activity Score (DAS) and Health Assessment Questionnaire (HAQ) over time were assessed using linear mixed models during maximum 6 or maximum 12 months from baseline. Treatment survival was assessed using multiple failure-times Cox regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data were included from 701 ACPA\u2012\/erosions\u2012, 334 ACPA\u2012\/erosions+, 1585 ACPA+\/erosions\u2012 and 1993 ACPA+\/erosions+ patients. We found statistically significant differences in DAS and HAQ change over time between the four groups, both after maximum follow-up durations of 6 and of 12 months, but after stratification differences proved small and not clinically meaningful. Patients in the ACPA\u2012\/erosions\u2012 group were less likely to switch treatment compared with the ACPA+\/erosions\u2012 reference group (p&lt;0.001). The other two ACPA\/erosions groups did not differ from the reference group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this analysis of worldwide real life data, we found statistically significant, but clinically irrelevant differences in treatment response to initial disease modifying anti-rheumatic drug therapies as measured by DAS and HAQ in ACPA\u2012\/erosions\u2012, ACPA\u2012\/erosions+, ACPA+\/erosions\u2012 and ACPA+\/erosions+ rheumatoid arthritis patients. However, after maximum follow-up durations of 6 and 12 months all groups had a similar response to initial treatment, but with a lower likelihood to switch treatment for ACPA\u2012\/erosions\u2012 patients during the first year of follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-000969","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T06:15:19Z","timestamp":1564553719000},"page":"e000969","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura C","family":"Couto","sequence":"additional","affiliation":[{"name":"Hospital Sao Teot\u00f3nio, Viseu, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimmisha","family":"Govind","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Chopra","sequence":"additional","affiliation":[{"name":"Center for Rheumatic Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Salomon Escoto","sequence":"additional","affiliation":[{"name":"Univeristy of Massaschusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Murphy","sequence":"additional","affiliation":[{"name":"University Hospital Wishaw, Wishaw, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom WJ","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia F","family":"Allaart","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"2025090313081344000_5.2.e000969.1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000172","article-title":"Predictive factors of radiological progression after 2\u2005years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study","volume":"2","author":"Akdemir","year":"2016","journal-title":"RMD Open"},{"key":"2025090313081344000_5.2.e000969.2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14397595.2016.1265726","article-title":"Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy","volume":"27","author":"Hirano","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2025090313081344000_5.2.e000969.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2025090313081344000_5.2.e000969.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.23364"},{"key":"2025090313081344000_5.2.e000969.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01300-7"},{"key":"2025090313081344000_5.2.e000969.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121160"},{"key":"2025090313081344000_5.2.e000969.7","doi-asserted-by":"crossref","unstructured":"Albrecht K , Zink A . Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther 2017;19.doi:10.1186\/s13075-017-1266-4","DOI":"10.1186\/s13075-017-1266-4"},{"key":"2025090313081344000_5.2.e000969.8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000649","article-title":"Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis","volume":"4","author":"Akdemir","year":"2018","journal-title":"RMD Open"},{"key":"2025090313081344000_5.2.e000969.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211375"},{"key":"2025090313081344000_5.2.e000969.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.05.003"},{"key":"2025090313081344000_5.2.e000969.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141586"},{"key":"2025090313081344000_5.2.e000969.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.38012"},{"key":"2025090313081344000_5.2.e000969.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130074"},{"key":"2025090313081344000_5.2.e000969.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025090313081344000_5.2.e000969.15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/03009742.2011.594964","article-title":"Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression","volume":"41","author":"Dirven","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"5 Suppl 101","key":"2025090313081344000_5.2.e000969.16","first-page":"S87","article-title":"Ten years of Meteor (an international rheumatoid arthritis registry): development, research opportunities and future perspectives","volume":"34","author":"Bergstra","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313081344000_5.2.e000969.17","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"2025090313081344000_5.2.e000969.18","first-page":"167","article-title":"The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation","volume":"30","author":"Bruce","year":"2003","journal-title":"J Rheumatol"},{"key":"2025090313081344000_5.2.e000969.19","unstructured":"How do I analyze multiple failure-time data using Stata? Available: https:\/\/www.stata.com\/support\/faqs\/statistics\/multiple-failure-time-data\/"},{"key":"2025090313081344000_5.2.e000969.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000245","article-title":"Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data","volume":"2","author":"Granger","year":"2016","journal-title":"RMD Open"},{"key":"2025090313081344000_5.2.e000969.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.22640"},{"key":"2025090313081344000_5.2.e000969.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110169"},{"key":"2025090313081344000_5.2.e000969.23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/acr.23497","article-title":"Is Anti-Citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than Anti-Citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 Onwar","volume":"70","author":"Boer","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090313081344000_5.2.e000969.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.120899"},{"key":"2025090313081344000_5.2.e000969.25","unstructured":"Tobacco Atlas . The tobacco atlas. Available: http:\/\/www.tobacoatlas.org\/country-data\/india\/"},{"key":"2025090313081344000_5.2.e000969.26","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.103139"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:08:22Z","timestamp":1756930102000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,7,30]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/rmdopen-2019-000969"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000969","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}